Apitegromab

Human clinical Muscle & Bone Health 3 sources

Apitegromab is a fully human monoclonal antibody designed to selectively inhibit the activation of myostatin, a protein that limits muscle growth. Research shows it has the potential to improve motor function and preserve muscle mass in patients with spinal muscular atrophy (SMA) when used alongside standard therapies.

01Dosing reference

Amount

20 mg/kg

Frequency

Once every 4 weeks via IV infusion

Cycle

Continuous treatment in clinical trial settings

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Binding to Latent Myostatin

Apitegromab specifically binds to the pro- and latent forms of myostatin (GDF8) in the extracellular matrix.

Inhibition of Activation

By binding to these precursor forms, it prevents the proteolytic cleavage required to release mature, active myostatin.

Muscle Growth Promotion

Reduced active myostatin signaling removes the natural brake on muscle growth, promoting muscle preservation and strength.

03Human evidence

Improved motor function in SMA patients

In the Phase 2 TOPAZ trial, patients with Type 2 and Type 3 SMA showed sustained improvements in the Hammersmith Functional Motor Scale Expanded (HFMSE) scores over 12 to 36 months.

Favorable safety and tolerability profile

Clinical trials have demonstrated that Apitegromab is generally well-tolerated, with no dose-limiting toxicities identified in early-phase studies.

04Preclinical evidence

Increased muscle mass and function in SMA models

In pharmacological mouse models of SMA, inhibiting myostatin activation led to significant increases in muscle mass and improvements in motor function.

High selectivity for myostatin

In vitro assays showed Apitegromab selectively targets myostatin activation without affecting the closely related GDF11, reducing the risk of off-target effects.

05What is known vs. unknown

Reasonably established

Apitegromab is a highly selective inhibitor of myostatin activation, targeting the latent form rather than the mature protein.
It is being investigated primarily as an add-on therapy to SMN upregulators (like nusinersen) for Spinal Muscular Atrophy (SMA).
The FDA has granted it Fast Track, Orphan Drug, and Rare Pediatric Disease designations for the treatment of SMA.
It is administered via intravenous (IV) infusion in clinical settings.

Unknowns & limits

Long-term safety and efficacy beyond the multi-year extension studies are still being evaluated in the ongoing Phase 3 SAPPHIRE trial.
Its efficacy as a standalone monotherapy for SMA, without concurrent SMN upregulator treatment, is not fully established.
The potential benefits of Apitegromab in other muscle-wasting conditions beyond SMA require further clinical validation.

06Safety & regulatory context

Regulatory statusApitegromab is an investigational drug and is not yet FDA-approved for any indication. In clinical trials, it has been generally well-tolerated. The most common adverse events reported include headache, pyrexia (fever), upper respiratory tract infections, and cough. Because it selectively targets myostatin activation rather than blocking the ActRII receptor, it is believed to have a lower risk of off-target effects compared to broader pathway inhibitors. It currently holds Orphan Drug and Fast Track designations from the FDA for SMA.

07Compared with Bimagrumab

Apitegromab vs. Bimagrumab

Key difference

Apitegromab selectively targets the activation of myostatin specifically, whereas bimagrumab blocks the ActRII receptor, affecting multiple ligands including myostatin and activin.

When researchers discuss each

Apitegromab is discussed for highly targeted muscle preservation in SMA to minimize off-target effects, while bimagrumab is often discussed for broader metabolic and muscle-wasting conditions.

08Glossary

Myostatin

A protein produced by muscle cells that acts as a negative regulator of muscle growth, essentially telling the body to stop building muscle.

Monoclonal Antibody

A laboratory-produced molecule engineered to serve as a substitute antibody that can bind to a specific target in the body.

Spinal Muscular Atrophy (SMA)

A genetic disorder characterized by the loss of motor neurons, leading to progressive muscle weakness and atrophy.

09Knowledge check

Q1How does Apitegromab differ from traditional myostatin inhibitors?

Q2What is the primary clinical indication currently being investigated for Apitegromab?

Q3Which statement about the long-term effects of Apitegromab is best supported by the dossier?

Q4According to the dossier, how does Apitegromab’s mechanism compare with bimagrumab?

Q5Which regulatory and safety description of Apitegromab is consistent with the dossier?

10Sources

More in Muscle & Bone Health

See all

IGF-1 LR3

Muscle & Bone Health

Early human

IGF-1 LR3 is a synthetic, modified version of Insulin-like Growth Factor-1 with an extended half-life and increased potency. Research highlights its ability to promote muscle cell hyperplasia (growth of new muscle cells), enhance protein synthesis, and improve recovery by resisting deactivation by IGF-binding proteins.

20-50 mcg per day

GDF-8 Myostatin Inhibitor

Muscle & Bone Health

Early human

GDF-8 (Growth Differentiation Factor 8), commonly known as myostatin, is a protein that naturally inhibits muscle growth. Myostatin inhibitors are compounds designed to block this protein, thereby promoting significant muscle hypertrophy and preventing muscle wasting in various research models.

1 mg - 3 mg (highly variable depending on specific peptide/antibody)

ACE-031

Muscle & Bone Health

Early human

ACE-031 is an investigational protein therapeutic designed to build muscle and increase strength by inhibiting signaling through the activin receptor type IIB (ActRIIB). Research primarily focused on its potential to treat muscle-wasting diseases like Duchenne muscular dystrophy, though clinical trials were halted due to safety concerns involving bleeding.

1-3 mg/kg (in clinical trial settings)

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.